Clinical Trials Browser

Neoplasm Metastasis, Neoplasms

NCT03629886 2024-03-15

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

Phase 4 Completed

6,051 enrolled 11 charts

Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms

NCT06207175 2024-01-23

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Phase 3 Unknown

1,260 enrolled

Papillomavirus Infections

NCT04965350 2023-04-13

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

Phase 3 Completed

1,100 enrolled

Papillomavirus Infections

NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Phase 2 Completed

780 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Phase 1 Completed

160 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05672966 2023-01-06

Phase I Clinical Trial of a Candidate HPV Vaccine

Phase 1 Unknown

40 enrolled

Papillomavirus Infections

NCT05668572 2023-01-04

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Phase 3 Unknown

12,000 enrolled

Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase 3 Active not recruiting

2,750 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT02529930 2022-07-13

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

Phase 1/2 Completed

34 enrolled

Gynecologic

High Grade Cervical Intraepithelial Neoplasia

NCT05426148 2022-06-29

Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

Phase 4 Completed

540 enrolled

Gynecologic

Persistent Infection, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01798056 2021-05-13

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Phase 3 Completed

237 enrolled 20 charts

Herpes Zoster

NCT01031069 2020-07-21

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Phase 4 Completed

873 enrolled 34 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01984697 2018-08-08

V503-010

Phase 3 Completed

1,518 enrolled 44 charts

Papillomavirus Infections

NCT00325130 2015-03-12

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Phase 3 Completed

1,042 enrolled 26 charts

Diphtheria, Meningitis, Neoplasms, Glandular and Epithelial, Tetanus, Whooping Cough

Clinical Trials

Autologous TLPO Vaccine Basket

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Phase I Clinical Trial of a Candidate HPV Vaccine

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

V503-010

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)